{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T22:33:52Z","timestamp":1776119632451,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"7362","license":[{"start":{"date-parts":[[2011,8,31]],"date-time":"2011-08-31T00:00:00Z","timestamp":1314748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2011,8,31]],"date-time":"2011-08-31T00:00:00Z","timestamp":1314748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2011,9,1]]},"DOI":"10.1038\/nature10358","type":"journal-article","created":{"date-parts":[[2011,8,30]],"date-time":"2011-08-30T12:10:25Z","timestamp":1314706225000},"page":"99-102","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":456,"title":["Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans"],"prefix":"10.1038","volume":"477","author":[{"given":"Caroline J.","family":"Breitbach","sequence":"first","affiliation":[]},{"given":"James","family":"Burke","sequence":"additional","affiliation":[]},{"given":"Derek","family":"Jonker","sequence":"additional","affiliation":[]},{"given":"Joe","family":"Stephenson","sequence":"additional","affiliation":[]},{"given":"Andrew R.","family":"Haas","sequence":"additional","affiliation":[]},{"given":"Laura Q. M.","family":"Chow","sequence":"additional","affiliation":[]},{"given":"Jorge","family":"Nieva","sequence":"additional","affiliation":[]},{"given":"Tae-Ho","family":"Hwang","sequence":"additional","affiliation":[]},{"given":"Anne","family":"Moon","sequence":"additional","affiliation":[]},{"given":"Richard","family":"Patt","sequence":"additional","affiliation":[]},{"given":"Adina","family":"Pelusio","sequence":"additional","affiliation":[]},{"given":"Fabrice","family":"Le Boeuf","sequence":"additional","affiliation":[]},{"given":"Joe","family":"Burns","sequence":"additional","affiliation":[]},{"given":"Laura","family":"Evgin","sequence":"additional","affiliation":[]},{"given":"Naomi","family":"De Silva","sequence":"additional","affiliation":[]},{"given":"Sara","family":"Cvancic","sequence":"additional","affiliation":[]},{"given":"Terri","family":"Robertson","sequence":"additional","affiliation":[]},{"given":"Ji-Eun","family":"Je","sequence":"additional","affiliation":[]},{"given":"Yeon-Sook","family":"Lee","sequence":"additional","affiliation":[]},{"given":"Kelley","family":"Parato","sequence":"additional","affiliation":[]},{"given":"Jean-Simon","family":"Diallo","sequence":"additional","affiliation":[]},{"given":"Aaron","family":"Fenster","sequence":"additional","affiliation":[]},{"given":"Manijeh","family":"Daneshmand","sequence":"additional","affiliation":[]},{"given":"John C.","family":"Bell","sequence":"additional","affiliation":[]},{"given":"David H.","family":"Kirn","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2011,8,31]]},"reference":[{"key":"BFnature10358_CR1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/nrc2545","volume":"9","author":"DH Kirn","year":"2009","unstructured":"Kirn, D. H. & Thorne, S. H. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nature Rev. Cancer 9, 64\u201371 (2009)","journal-title":"Nature Rev. Cancer"},{"key":"BFnature10358_CR2","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1038\/nrc1750","volume":"5","author":"KA Parato","year":"2005","unstructured":"Parato, K. A., Senger, D., Forsyth, P. A. & Bell, J. C. Recent progress in the battle between oncolytic viruses and tumours. Nature Rev. Cancer 5, 965\u2013976 (2005)","journal-title":"Nature Rev. Cancer"},{"key":"BFnature10358_CR3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/ncponc0736","volume":"4","author":"TC Liu","year":"2007","unstructured":"Liu, T. C., Galanis, E. & Kirn, D. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat. Clin. Pract. Oncol. 4, 101\u2013117 (2007)","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"BFnature10358_CR4","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1099\/0022-1317-78-8-2041","volume":"78","author":"A Vanderplasschen","year":"1997","unstructured":"Vanderplasschen, A., Hollinshead, M. & Smith, G. L. Antibodies against vaccinia virus do not neutralize extracellular enveloped virus but prevent virus release from infected cells and comet formation. J. Gen. Virol. 78, 2041\u20132048 (1997)","journal-title":"J. Gen. Virol."},{"key":"BFnature10358_CR5","doi-asserted-by":"publisher","first-page":"7544","DOI":"10.1073\/pnas.95.13.7544","volume":"95","author":"A Vanderplasschen","year":"1998","unstructured":"Vanderplasschen, A., Mathew, E., Hollinshead, M., Sim, R. B. & Smith, G. L. Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope. Proc. Natl Acad. Sci. USA 95, 7544\u20137549 (1998)","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnature10358_CR6","first-page":"1317","volume":"63","author":"LM Wein","year":"2003","unstructured":"Wein, L. M., Wu, J. T. & Kirn, D. H. Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment: implications for virus design and delivery. Cancer Res. 63, 1317\u20131324 (2003)","journal-title":"Cancer Res."},{"key":"BFnature10358_CR7","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1146\/annurev.micro.57.030502.091037","volume":"57","author":"GL Smith","year":"2003","unstructured":"Smith, G. L., Murphy, B. J. & Law, M. Vaccinia virus motility. Annu. Rev. Microbiol. 57, 323\u2013342 (2003)","journal-title":"Annu. Rev. Microbiol."},{"key":"BFnature10358_CR8","doi-asserted-by":"publisher","first-page":"52210","DOI":"10.1074\/jbc.M411033200","volume":"279","author":"GC Katsafanas","year":"2004","unstructured":"Katsafanas, G. C. & Moss, B. Vaccinia virus intermediate stage transcription is complemented by Ras-GTPase-activating protein SH3 domain-binding protein (G3BP) and cytoplasmic activation\/proliferation-associated protein (p137) individually or as a heterodimer. J. Biol. Chem. 279, 52210\u201352217 (2004)","journal-title":"J. Biol. Chem."},{"key":"BFnature10358_CR9","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1172\/JCI200523220","volume":"115","author":"H Yang","year":"2005","unstructured":"Yang, H. et al. Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction. J. Clin. Invest. 115, 379\u2013387 (2005)","journal-title":"J. Clin. Invest."},{"key":"BFnature10358_CR10","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","volume":"100","author":"D Hanahan","year":"2000","unstructured":"Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57\u201370 (2000)","journal-title":"Cell"},{"key":"BFnature10358_CR11","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/sj.cgt.7700066","volume":"6","author":"MJ Mastrangelo","year":"1999","unstructured":"Mastrangelo, M. J. et al. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther. 6, 409\u2013422 (1999)","journal-title":"Cancer Gene Ther."},{"key":"BFnature10358_CR12","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.ymthe.2006.05.008","volume":"14","author":"JH Kim","year":"2006","unstructured":"Kim, J. H. et al. Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol. Ther. 14, 361\u2013370 (2006)","journal-title":"Mol. Ther."},{"key":"BFnature10358_CR13","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/317813a0","volume":"317","author":"RM Buller","year":"1985","unstructured":"Buller, R. M., Smith, G. L., Cremer, K., Notkins, A. L. & Moss, B. Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. Nature 317, 813\u2013815 (1985)","journal-title":"Nature"},{"key":"BFnature10358_CR14","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S1470-2045(08)70107-4","volume":"9","author":"BH Park","year":"2008","unstructured":"Park, B. H. et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol. 9, 533\u2013542 (2008)","journal-title":"Lancet Oncol."},{"key":"BFnature10358_CR15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/j.1365-2362.1992.tb01934.x","volume":"22","author":"D Hovgaard","year":"1992","unstructured":"Hovgaard, D., Mortensen, B. T., Schifter, S. & Nissen, N. I. Clinical pharmacokinetic studies of a human haemopoietic growth factor, GM-CSF. Eur. J. Clin. Invest. 22, 45\u201349 (1992)","journal-title":"Eur. J. Clin. Invest."},{"key":"BFnature10358_CR16","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1200\/JCO.2006.07.3049","volume":"25","author":"H Choi","year":"2007","unstructured":"Choi, H. et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J. Clin. Oncol. 25, 1753\u20131759 (2007)","journal-title":"J. Clin. Oncol."},{"key":"BFnature10358_CR17","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/annonc\/mdh059","volume":"15","author":"MJ Byrne","year":"2004","unstructured":"Byrne, M. J. & Nowak, A. K. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann. Oncol. 15, 257\u2013260 (2004)","journal-title":"Ann. Oncol."},{"key":"BFnature10358_CR18","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1126\/science.2047875","volume":"252","author":"B Moss","year":"1991","unstructured":"Moss, B. Vaccinia virus: a tool for research and vaccine development. Science 252, 1662\u20131667 (1991)","journal-title":"Science"},{"key":"BFnature10358_CR19","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/nature08956","volume":"464","author":"ME Davis","year":"2010","unstructured":"Davis, M. E. et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464, 1067\u20131070 (2010)","journal-title":"Nature"},{"key":"BFnature10358_CR20","first-page":"4656","volume":"62","author":"KW Peng","year":"2002","unstructured":"Peng, K. W. et al. Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res. 62, 4656\u20134662 (2002)","journal-title":"Cancer Res."},{"key":"BFnature10358_CR21","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.ymthe.2004.06.158","volume":"10","author":"JA McCart","year":"2004","unstructured":"McCart, J. A. et al. Oncolytic vaccinia virus expressing the human somatostatin receptor SSTR2: molecular imaging after systemic delivery using 111In-pentetreotide. Mol. Ther. 10, 553\u2013561 (2004)","journal-title":"Mol. Ther."},{"key":"BFnature10358_CR22","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1038\/mt.2009.218","volume":"17","author":"P Msaouel","year":"2009","unstructured":"Msaouel, P. et al. Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter. Mol. Ther. 17, 2041\u20132048 (2009)","journal-title":"Mol. Ther."},{"key":"BFnature10358_CR23","first-page":"8751","volume":"61","author":"JA McCart","year":"2001","unstructured":"McCart, J. A. et al. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res. 61, 8751\u20138757 (2001)","journal-title":"Cancer Res."},{"key":"BFnature10358_CR24","doi-asserted-by":"publisher","first-page":"3350","DOI":"10.1172\/JCI32727","volume":"117","author":"SH Thorne","year":"2007","unstructured":"Thorne, S. H. et al. Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963. J. Clin. Invest. 117, 3350\u20133358 (2007)","journal-title":"J. Clin. Invest."},{"key":"BFnature10358_CR25","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1038\/mt.2010.140","volume":"18","author":"SH Thorne","year":"2010","unstructured":"Thorne, S. H. et al. Targeting localized immune suppression within the tumor through repeat cycles of immune cell-oncolytic virus combination therapy. Mol. Ther. 18, 1698\u20131705 (2010)","journal-title":"Mol. Ther."},{"key":"BFnature10358_CR26","first-page":"365","volume":"132","author":"S Rozen","year":"2000","unstructured":"Rozen, S. & Skaletsky, H. Primer3 on the WWW for general users and for biologist programmers. Methods Mol. Biol. 132, 365\u2013386 (2000)","journal-title":"Methods Mol. Biol."},{"key":"BFnature10358_CR27","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1128\/JCM.42.2.601-609.2004","volume":"42","author":"DA Kulesh","year":"2004","unstructured":"Kulesh, D. A. et al. Smallpox and pan-orthopox virus detection by real-time 3\u2032-minor groove binder TaqMan assays on the Roche LightCycler and the Cepheid Smart Cycler platforms. J. Clin. Microbiol. 42, 601\u2013609 (2004)","journal-title":"J. Clin. Microbiol."},{"key":"BFnature10358_CR28","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse, P. et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92, 205\u2013216 (2000)","journal-title":"J. Natl. Cancer Inst."},{"key":"BFnature10358_CR29","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.2214\/ajr.183.6.01831619","volume":"183","author":"H Choi","year":"2004","unstructured":"Choi, H. et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR Am. J. Roentgenol. 183, 1619\u20131628 (2004)","journal-title":"AJR Am. J. Roentgenol."},{"key":"BFnature10358_CR30","doi-asserted-by":"publisher","first-page":"505","DOI":"10.4324\/9781410607034","volume-title":"Research Design and Statistical Analysis","author":"JLW Myers","year":"2003","unstructured":"Myers, J. L. W. & Arnold, D. Research Design and Statistical Analysis. 2nd edn, 505\u2013512 (Laurence Erlbaum, 2003)"}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/nature10358.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nature10358","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nature10358.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T13:25:26Z","timestamp":1684848326000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nature10358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,31]]},"references-count":30,"journal-issue":{"issue":"7362","published-print":{"date-parts":[[2011,9,1]]}},"alternative-id":["BFnature10358"],"URL":"https:\/\/doi.org\/10.1038\/nature10358","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.13199980.14542093","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.13199980.14743095","asserted-by":"object"}]},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,31]]},"assertion":[{"value":"25 February 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2011","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.J.B., J.B., A.M., A.P., T.R. and D.H.K. are employees of Jennerex Inc. and hold stock options in Jennerex Inc. T.-H.H. and J.C.B. consult for and hold stock options in Jennerex Inc. R.P., Y.-S.L. and M.D. consult for Jennerex Inc.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}